| Population-based mechanistic prediction of oral drug absorption M Jamei, D Turner, J Yang, S Neuhoff, S Polak, A Rostami-Hodjegan, ... The AAPS journal 11, 225-237, 2009 | 538 | 2009 |
| In vivo methods for drug absorption–comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient … E Sjögren, B Abrahamsson, P Augustijns, D Becker, MB Bolger, ... European Journal of Pharmaceutical Sciences 57, 99-151, 2014 | 321 | 2014 |
| pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug–drug interactions S Neuhoff, AL Ungell, I Zamora, P Artursson Pharmaceutical research 20, 1141-1148, 2003 | 273 | 2003 |
| Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA pKaflux method A Avdeef, P Artursson, S Neuhoff, L Lazorova, J Gråsjö, S Tavelin European journal of pharmaceutical sciences 24 (4), 333-349, 2005 | 256 | 2005 |
| Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “Advanced Dissolution, Absorption … A S. Darwich, S Neuhoff, M Jamei, A Rostami-Hodjegan Current drug metabolism 11 (9), 716-729, 2010 | 214 | 2010 |
| A mechanistic framework for in vitro–in vivo extrapolation of liver membrane transporters: prediction of drug–drug interaction between rosuvastatin and cyclosporine M Jamei, F Bajot, S Neuhoff, Z Barter, J Yang, A Rostami-Hodjegan, ... Clinical pharmacokinetics 53, 73-87, 2014 | 191 | 2014 |
| Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment … J Bentz, MP O’Connor, D Bednarczyk, JA Coleman, C Lee, J Palm, ... Drug metabolism and disposition 41 (7), 1347-1366, 2013 | 184 | 2013 |
| pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers S Neuhoff, AL Ungell, I Zamora, P Artursson European Journal of Pharmaceutical Sciences 25 (2-3), 211-220, 2005 | 176 | 2005 |
| Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro–in vivo extrapolation of oral drug absorption MD Harwood, S Neuhoff, GL Carlson, G Warhurst, A Rostami‐Hodjegan Biopharmaceutics & drug disposition 34 (1), 2-28, 2013 | 130 | 2013 |
| Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug–drug interactions HJ Burt, S Neuhoff, L Almond, L Gaohua, MD Harwood, M Jamei, ... European journal of pharmaceutical sciences 88, 70-82, 2016 | 121 | 2016 |
| Proteomic quantification of human blood–brain barrier SLC and ABC transporters in healthy individuals and dementia patients ZM Al-Majdoub, H Al Feteisi, B Achour, S Warwood, S Neuhoff, ... Molecular pharmaceutics 16 (3), 1220-1233, 2019 | 120 | 2019 |
| Physiologically‐based pharmacokinetic models for evaluating membrane transporter mediated drug–drug interactions: current capabilities, case studies, future opportunities, and … KS Taskar, V Pilla Reddy, H Burt, MM Posada, M Varma, M Zheng, ... Clinical Pharmacology & Therapeutics 107 (5), 1082-1115, 2020 | 115 | 2020 |
| Abundance of hepatic transporters in Caucasians: a meta-analysis HJ Burt, AE Riedmaier, MD Harwood, HK Crewe, KL Gill, S Neuhoff Drug metabolism and disposition 44 (10), 1550-1561, 2016 | 87 | 2016 |
| Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1‐Related Variability in Pharmacodynamics of Rosuvastatin RH Rose, S Neuhoff, K Abduljalil, M Chetty, A Rostami‐Hodjegan, ... CPT: pharmacometrics & systems pharmacology 3 (7), 1-9, 2014 | 84 | 2014 |
| Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying … L Gaohua, S Neuhoff, TN Johnson, A Rostami-Hodjegan, M Jamei Drug metabolism and pharmacokinetics 31 (3), 224-233, 2016 | 81 | 2016 |
| Accounting for transporters in renal clearance: towards a mechanistic kidney model (Mech KiM) S Neuhoff, L Gaohua, H Burt, M Jamei, L Li, GT Tucker, ... Transporters in drug development: discovery, optimization, clinical study …, 2013 | 81 | 2013 |
| Application of permeability-limited physiologically-based pharmacokinetic models: part I–digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux S Neuhoff, KR Yeo, Z Barter, M Jamei, DB Turner, A Rostami-Hodjegan Journal of pharmaceutical sciences 102 (9), 3145-3160, 2013 | 76 | 2013 |
| Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. S Neuhoff, P Langguth, C Dressler, TB Andersson, CG Regårdh, ... International journal of clinical pharmacology and therapeutics 38 (4), 168-179, 2000 | 76 | 2000 |
| New approach methodologies (NAMs) for human-relevant biokinetics predictions: Meeting the paradigm shift in toxicology towards an animal-free chemical risk assessment A Punt, H Bouwmeester, BJ Blaauboer, S Coecke, B Hakkert, ... Altex 37 (4), 607-622, 2020 | 70 | 2020 |
| Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells S Neuhoff, P Artursson, I Zamora, AL Ungell Pharmaceutical research 23, 350-359, 2006 | 69 | 2006 |
Amin Rostami-HodjeganProfessor of Systems Pharmacology, University of Manchester, UKEmail yang diverifikasi di manchester.ac.uk
